Boundless Bio, Inc.
corporate_fare Company Profile
Boundless Bio, Inc. (NASDAQ:BOLD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for BOLD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for BOLD spans 425, S-4, 8-K, 10-Q.
Recent high-impact activity:
- Boundless Bio Merger Partner Serapha Reports Positive Interim SERP-01 Base Editing Data
- Boundless Bio Files S-4 for Reverse Merger with Serapha Bio: 96.2% Dilution, $44-48M Dividend, and Beam Litigation Risk
- Boundless Bio Amends Serapha Bio Merger Terms: Adds RSU Conversion, Pre-Funded Warrants, and Lower Voting Threshold
- Boundless Bio Q2 2026: $72.6M Cash, $37.2M Loss, Merger with Serapha Bio on Track
- 10% Owner Kevin Tang Buys $714K in Boundless Bio Shares Post-Merger Announcement
Financial Snapshot
Short Interest & Short Volume
4.62 days to coverFINRA reported short interest of 788,477 shares in BOLD as of the October 15, 2026 settlement, a 1.3% increase from the prior period — about 4.6 days to cover at its recent average daily volume. On October 30, 2026, 67.2% of BOLD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BOLD, detected from its recent SEC filings · based on capital-structure filings through 2026-05-08.
Cash Runway Significantly Reduced · Major Lease Termination and Cash Outflow
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →